Background: The global, single-arm, phase II KEYNOTE-629 trial (NCT03284424) studied the safety and efficacy of pembrolizumab in patients with recurrent/metastatic (R/M) cSCC. Methods: Patients with R/M cSCC received pembrolizumab 200 mg Q3W for up to 35 infusions (Grob JJ et al. J Clin Oncol. 2019;37(suppl; abstr TPS9598)). The primary end point was ORR by blinded independent central review per RECIST v1.1. Secondary end points were DOR, DCR, PFS, OS, and safety. DOR, PFS, and OS were estimated using the Kaplan-Meier method. Results of an interim analysis are presented. Results: Of 105 patients, 76.2% were male, median age was 72 years, 86.7% had previously received 1 line of systemic therapy, and 74.3% had previously undergone radiation. At data cutoff (April 8, 2019), median duration of follow-up was 9.5 months (range, 0.4-16.3 months). ORR was 34.3% (95% CI, 25.3%-44.2%); 4 patients (3.8%) achieved CR (95% CI, 1.0%-9.5%), and 32 patients (30.5%) achieved PR (95% CI, 21.9%-40.2%). Median DOR was not reached (range, 2.7-13.1þ months). Of the 36 responders, 31 patients and 7 patients had a minimum follow-up of 6 months and 12 months, respectively, after achieving response; 25 (79.5%) and 1 (65.6%) were estimated to have ongoing responses at > 6 months and >12 months, respectively. DCR (CR þ PR þ stable disease 12 weeks) was 52.4% (95% CI, 42.4%-62.2%). Median PFS was 6.9 months (95% CI, 3.1-8.5 months); 12-month PFS rate was 32.4%. Median OS was not reached (95% CI, 10.7 months-not reached); 12-month OS rate of 60.3%. Treatment-related adverse events (TRAEs) occurred in 70 patients (66.7%), and 6 patients (5.7%) had grade 3-5 TRAEs; 1 patient died of treatment-related cranial nerve neuropathy. The most common TRAEs were pruritus (14.3%), asthenia (13.3%), and fatigue (12.4%). Conclusions: Pembrolizumab demonstrated a clinically meaningful ORR (34.3%), durable responses, and remarkable PFS and OS in patients with R/M cSCC, most of whom were heavily pretreated. Treatment was well tolerated, and the safety profile was generally consistent with that of other pembrolizumab monotherapy studies; no new safety signals were identified. These data support pembrolizumab for the treatment of R/M cSCC.
Background: The MAPK pathway is constitutively activated in uveal melanoma (UM), a disease for which there remains no standard of care for metastatic disease. In a randomised phase II clinical trial, selumetinib (AZD6244, ARRY-142886), a MEKi, showed superiority vs dacarbazine (DTIC). A phase III study of the combination of selumetinib (SEL) þ DTIC however failed to show superiority over DTIC alone. Pre-clinical data support synergistic cytotoxic activity for MEKi þ taxane combinations in a number of cancer cell line models and suggest that interrupting selumetinib before taxane exposure may be beneficial. Methods: Following ethical approval, 77 patients with metastatic UM who had not received previous chemotherapy were randomised to either A: SEL 75mg bd po B: SEL 75mg bd po þ PT 80mg/m 2 weeks 1, 2 and 3 (q28) or C: SEL 75mg bd po interrupted for 2 days before exposure to PT 80mg/m 2 weeks 1, 2, 3 (q28) at 13 UK and 1 German sites. Primary endpoint was PFS; OS, ORR and toxicity were secondary endpoints. After an amendment, arms B & C were combined and compared to arm A for PFS, OS and ORR using intention to treat analyses. Reflecting the pooled comparison, the sample size was re-adjusted to detect hazard ratio: 0.55, 80% power at 1-sided 5% significance level. Sensitivity analysis was performed to explore whether there were detectable differences in outcome between patients receiving continuous or interrupted SEL in combination with PT (arms B & C). Results: Primary analysis was triggered after 68 events. The median PFS in the combination arms B & C was 4.8 months (95% CI: 3.8 -5.6) compared with 3.4 months (95% CI: 2.0 -3.9) in the SEL alone arm A (hazard ratio 0.61 [90% CI 0.41 -0.92], 1-sided pvalue ¼ 0.022). ORR was 14% and 4% in arms B & C and A respectively. Median OS in arms B & C was 9 months and was not significantly different from arm A at 10 months (hazard ratio 0.98 [90% CI 0.58 -1.66], 1-sided p-value ¼ 0.469). SAEs and grade 3þ toxicities were similar between treatment arms. Conclusions: SelPac met its primary endpoint, demonstrating a statistically significant improvement in PFS for SEL þ PT without a significant increase in toxicity. ( 
